No abstract

These data suggest that YKL-40 is increased in the circulation and lungs of IPF patients, suggesting that this glycoprotein is associated with the pathophysiology of IPF.

No abstract

Summary.Relapse is a major cause of treatment failure in acute myeloid leukaemia (AML), and is usually accompanied by resistance to chemotherapy. To study whether relapse is accompanied by genetic alterations, we compared N-ras, p53 and FLT3 gene mutations in paired samples obtained at initial diagnosis and first relapse. 28 patients with relapsed AML were studied, and their duration of complete remission ranged from 133 to 989 d (mean 318 d). Karyotype changes were observed at relapse in 11 patients. Point mutations of the N-ras gene were positive at both stages (þ/þ) in three patients, positive at initial diagnosis and negative at relapse (þ/¹) in three patients, and negative at initial diagnosis and positive at relapse (¹/þ) in two patients. Internal tandem duplications of the FLT3 gene (FLT3/ITD) were þ/þ in five patients, þ/¹ in one patient, and ¹/þ in six patients. The p53 gene mutations were þ/þ in two patients, þ/¹ in one patient, and ¹/¹ in 25 patients. FLT3/ITD and mutant p53 at relapse were associated with short survival after relapse. These results indicate that relapse is frequently accompanied by molecular alterations that include the loss and/or acquisition of mutations. Thus relapse can be understood as clonal shift or collateral succession rather than clonal progression.

Changes in KRAS mutation status between preoperative and postoperative cfDNA may be a useful predictive biomarker for survival and treatment response.